| Entries |
| Document | Title | Date |
|---|
| 20080207752 | Poly (epsilon-caprolactone-co-methylmethacrylate), method for preparing the same using super critical fluid, and method for preparing therapeutic agent for skin diseases such as acne, atopy and athlete's foot comprising the same - A biodegradable polymer comprising a spherical poly (ε-caprolactone-co-methylmethacrylate) used in a therapeutic agent for skin diseases and a method for preparing the same, and a method for preparing the therapeutic agent for skin diseases having the particle size of 50 to 100 nm and a spherical shape comprising the poly (ε-caprolactone-co-methylmethacrylate) and salicylic acid. | 08-28-2008 |
| 20080234371 | Non-hygroscopic L-carnitine salts - Stable and non-hygroscopic L-carnitine salts of organic acids are provided, each of which is present as a true complex salt, having the formula: | 09-25-2008 |
| 20080249168 | Pharmaceutical composition for gout - A composition for hyperuricemia disease or a related disorder, use thereof and method of using thereof are provided. | 10-09-2008 |
| 20080262083 | ANTIBACTERIAL AGENTS - D-(threo)-1-aryl-2-disubstitutedacylamido-3-fluoro-1-propanol compounds compounds and analogues thereof (“Fenicol Compounds”), compositions comprising an effective amount of a Fenicol Compound, and methods for treating or preventing a bacterial infection in an animal comprising administering to an animal in need thereof an effective amount of a Fenicol Compound are disclosed. | 10-23-2008 |
| 20080275117 | Compositions and Methods Comprising Boswellia Species - In certain aspects the invention features novel compositions and pharmaceutical preparations of the same. In certain embodiments, the compositions comprise α- and/or β-boswellic acid and/or their C-acetates in an amount greater than 65% by weight. | 11-06-2008 |
| 20080306152 | COMPOSITIONS CONTAINING PRODRUGS OF FLORFENICOL AND METHODS OF USE - The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration. | 12-11-2008 |
| 20090012162 | Composition for treating or preventing cell degeneration using at least one molecule capable of maintaining adhesion molecule expression reversibility and vascular endothelium actin fibre polymerisation - The invention relates to the use of a molecule selected from the group which consists of geranyl acetate, geraniol, isomenthone, limonene or a mixture of at least two of the above, for preparing a drug for treating or preventing vascular endothelial cell senescence and subjacent tissue degeneration induced by repeated inflammatory episodes. Specifically, the drug is useful for treating vascular endothelial cell senescence and tissue degeneration induced by repeated inflammatory episodes resulting from the presence of cancer cells. | 01-08-2009 |
| 20090018192 | Methods for Repelling Arthropods Using Isolongifolenone Analogs - A method for for repelling arthropods involving treating an object or area with an arthropod repelling effective amount of at least one isolongifolenone analog (and optionally a carrier or carrier material). | 01-15-2009 |
| 20090042982 | METHOD FOR TREATING NEUROLOGICAL DISORDERS USING ACETONE DERIVATIVES - The present invention provides a method of treating neurological disorders, such as epilepsy, comprising administering an effect amount of an acetone derivative having the formula R | 02-12-2009 |
| 20090062385 | DEUTERIUM-ENRICHED FESOTERODINE - The present application describes deuterium-enriched fesoterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
| 20090069422 | COMPOSITION AND METHOD FOR INCREASING THE ANABOLIC STATE OF MUSCLE CELLS - A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle by substantially simultaneously maintaining blood and muscle physiological pH levels as well as increasing cellular concentrations of branched-chain amino acids. Both a composition and a method are provided by the present disclosure. | 03-12-2009 |
| 20090082443 | Use of fatty acid esters of glycerol combined with polylysine against gram-negative bacteria - The present invention relates to a method for the prevention and/or reduction of the presence, growth and/or activity of gram-negative bacteria comprising application of a composition comprising glycerol-based fatty acid esters and polylysine and/or salts of polylysine, wherein said glycerol-based fatty acid ester is used as antibacterial agent. The present invention further relates to the use of said composition as antibacterial agent in various products and applications ranging from technical products and personal-care products to food and drink products for animals and human consumption. | 03-26-2009 |
| 20090105337 | Esters of Florfenicol - The invention relates to compounds of formula (I): | 04-23-2009 |
| 20090124691 | INHIBITOR OF INCREASE IN POSTPRANDIAL BLOOD INSULIN LEVEL - The present invention provides an agent for inhibiting a postprandial increase in blood insulin level, wherein the agent containing a monoacylglycerol as an active ingredient. An agent of the invention for inhibiting a postprandial increase in blood insulin level contains a monoacylglycerol as an active ingredient. | 05-14-2009 |
| 20090156672 | Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities - Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as CpdA. The methods and compositions may be used for treating diseases, disorders, and conditions associated with glucocorticoid receptor activity, androgen receptor activity, or both, such as cancers, acne vulgaris, and alopecia. | 06-18-2009 |
| 20090170940 | Modified ethyl formate compositions and methods for soil fumigation - Slow-flow, modified ethyl formate compositions and methods for their use as pre-plant soil fumigants (controlling nematodes and other pathogens) are provided. The modifications include adding to ethyl formate a viscosity modifying thickening agent, and one or more substances which function as a co-solvent and dilution agent (the co-solvent and dilution may or may not be the same). The thickening agent increases the viscosity thereby slowing its flow or rate of transport through the soil. The co-solvent functions as the primary solvent for the viscosity modifying thickening agent. The dilution agent does two things. First, it is used to reduce the partial vapor pressure of the ethyl formate in the formulation, thereby slowing its evaporation rate. Second, it also slows the rate and amount of decomposition of the ethyl formate. The SFMEF compositions and methods do not have harmful ozone-depleting side effects and break down into two naturally-occurring, environmentally-friendly components. Thus they are useful as replacements for methyl bromide and other known ozone-depleting and/or highly toxic soil fumigants. | 07-02-2009 |
| 20090192223 | GIP SECRETION INHIBITOR - The object of the invention is to provide a GIP secretion inhibitor which is a useful drug or food ingredient. The present invention provides an agent for inhibiting postprandial GIP secretion contains a monoacylglycerol as an active ingredient. | 07-30-2009 |
| 20090192224 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF - The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C | 07-30-2009 |
| 20090215890 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS CONTAINING CARBOHYDRATE, LIPID OR AMINO ACID CARRIERS - The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs. | 08-27-2009 |
| 20090221702 | COMPOUNDS - The present invention provides the use of a compound of the Formula: (I) wherein R | 09-03-2009 |
| 20090239947 | Inhibition of proliferation and fibrotic response of activated corneal stromal cells - Provided herein are methods of preventing a fibrotic response and/or scarring in a wound, comprising administering to a subject a composition comprising an amount of an amide or ester of an alpha-ketoalkanoic acid effective to inhibit a proliferative and/or fibrotic response in the wound. In one instance, the wound is to a subject's cornea, such as a wound resulting from refractive surgery. In one embodiment, the amide or ester of an alpha-ketoalkanoic acid is ethyl pyruvate. | 09-24-2009 |
| 20090292018 | Dicarbonic Acid Derivatives, Metastasis Inhibitors and Agents Increasing Chemotherapeutic Activity of Anti-Tumor Preparations, Method for Enhancing the Cytostatic Efficiency and Metastasis Process Inhibiting Method - The invention relates to dicarbonic acid derivatives and concerns dicarbonic acid monooxydamines and dioxydamides, which are physiologically active substances and can be used as low-toxic and non-toxic agents for enhancing the anti-tumor and anti-metastasis effects of known cytostatics (cyclophosphane and cisplatin) in cytostatic chemotherapy of tumors. | 11-26-2009 |
| 20090326068 | Therapeutics for Cancer using 3-Bromopyruvate and other Selective Inhibitors of ATP Production - The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production for use in the invention. | 12-31-2009 |
| 20100022643 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS CONTAINING CARBOHYDRATE, LIPID OR AMINO ACID CARRIERS - The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs. | 01-28-2010 |
| 20100029764 | COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE-MEDIATED INTRACELLULAR SIGNAL TRANSDUCTION - Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and/or conformational changes in membranous structures (e.g., membrane proteins, receptors and/or other components) including G-protein coupled receptors (GPCRs), G-proteins, and/or intracellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). | 02-04-2010 |
| 20100076080 | Synthesis of Cyclohexane Derivatives Useful as Sensates in Consumer Products - The present invention provides synthetic routes for preparing various isomers of cyclohexane-based coolants, such as menthyl esters and menthanecarboxamide derivatives, in particular those substituted at the amide nitrogen, for example with an aromatic ring or aryl moiety. Such structures have high cooling potency and long lasting sensory effect, which make them useful in a wide variety of consumer products. One synthetic route involves a copper catalyzed coupling of a primary menthanecarboxamide with an aryl halide, such reaction working best in the presence of potassium phosphate and water. Using this synthetic route, specific isomers can be prepared including the menthanecarboxamide isomer having the same configuration as l-menthol and new isomers such as a neoisomer having opposite stereochemistry at the carboxamide (C-1) position. The neoisomer unexpectedly has potent and long lasting cooling effect. Preparation schemes for neoisomers of other menthyl derivatives which are useful as coolants, including esters, ethers, carboxy esters and other N-substituted carboxamides are also provided. | 03-25-2010 |
| 20100099762 | COMBINATION THERAPY - The present invention relates generally to a method of treating a psychiatric or neuropsychiatric condition in a mammal with a combination therapy. More particularly, the present invention relates to a combination therapy comprising an antipsychotic agent and a compound that increases levels of glutathione in the body. | 04-22-2010 |
| 20100130606 | PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation. | 05-27-2010 |
| 20100137434 | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer - The present disclosure relates to the discovery that compounds of the invention, particularly 3-bromopyruvate and related compounds, can be safely administered at concentrations effective for the treatment of cancer when formulated with an acidity of greater than or equal to pH of 2 and less than or equal to a pH of 6. Disclosed herein are novel and improved methods and compositions for the treatment of cancer using 3-halopyruvate and related compounds. | 06-03-2010 |
| 20100137435 | Monoacetyldiacylglycerol Derivative for the Treatment of Sepsis - The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against caner cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect of apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer. | 06-03-2010 |
| 20100184857 | ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATION AND THE TREATMENT OR PREVENTION OF GASTRIC TOXICITY - The invention provides hops ( | 07-22-2010 |
| 20100184858 | Hepatic fibrosis inhibitor - The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula: | 07-22-2010 |
| 20100204322 | METHOD OF TREATING AUTOIMMUNE DISEASES - A method of treating an autoimmune disease (for example, Systemic Lupus Erythematosus) comprises administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof. Methods of screening compounds useful for the treatment of autoimmune disease are also disclosed. | 08-12-2010 |
| 20100249230 | ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES - Disclosed is a method of synthesizing new optically pure heterocyclic compounds using Pd(0) catalyzed intramolecular cyclizations. Analogs of cyclopentanes, like isoxazoline-2-oxide and furan, with similar framework to the cyclopentanes act as anti-HIV and anticancer agents which opens a whole new field for application of these compounds. Starting from a meso-diol, optically pure compounds were prepared without utilizing chiral ligands at any stage of the synthesis. The stereochemical outcome of the product (>99% ee) was influenced by desymmetrization catalyzed by | 09-30-2010 |
| 20100280109 | LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT - The present disclosure relates to lipid compounds of formula (I): | 11-04-2010 |
| 20100280110 | (3R)-L-MENTHYL 3-HYDROXYBUTYRATE, PROCESS FOR PRODUCING THE SAME, AND SENSATE COMPOSITION COMPRISING THE SAME - The present invention provides a cooling component or sensate component which has further strong cooling intensity and is excellent in the persistency or refresh-feeling and cool-feeling, a sensate composition comprising the same, and various products comprising the sensate composition. The present invention relates to, as a cooling component or sensate component, (3R)-1-menthyl 3-hydroxybutyrate represented by the following formula (I): | 11-04-2010 |
| 20100311830 | Menthol Replacement - A method of producing in a composition adapted to be applied to the mucous membranes, the physiological effects of menthol at a reduced menthol concentration, by the partial replacement of menthol by a cooling and flavour blend, including
| 12-09-2010 |
| 20110015267 | METHODS FOR THE PREPARATION AND USE OF AQUEOUS SOLUTIONS OF MAGNESIUM VALPROATE HYDRATE AND L-CARNITINE - The present invention relates to methods for preparing liquid valproate compositions comprising solutions of a magnesium valproate and L-carnitine in water and administering said compositions to a subject in need of treatment with valproate and L-carnitine. The compositions of the invention are particularly useful treatments for infants, young children, women of child-bearing age, the aging, institutionalized patients, and patients having dysphagia who are receiving valproate treatment and are at high risk for valproate-related L-carnitine deficiency and cellular dysfunction and hepatotoxicity related thereto. | 01-20-2011 |
| 20110028546 | NOVEL ANTIMICROBIAL FORMULATIONS INCORPORATING ALKYL ESTERS OF FATTY ACIDS AND NANOEMULSIONS THEREOF - The present invention relates to a novel antimicrobial composition and method comprising any of the C1-C4 monohydric alcohol esters of C8 to C22 fatty acids, and most preferably the C1-C4 monohydric alcohol esters of C8 to C12 fatty acids, namely, caprylic, capric, and lauric fatty acids. Specifically the invention is related to a composition and method to disinfect various surfaces and substrates including the surfaces of food products, animal and human tissue and appendages, inanimate objects of various compositions, and also enclosed spaces. The invention can be incorporated into various media including liquids, gels, powders, paints, sealants, and the like and can be in the form of emulsions including nanoemulsions. | 02-03-2011 |
| 20110034554 | COMPOSITIONS AND METHODS FOR TREATING MACULAR DEGENERATION - Methods of retarding formation of a lipofuscin pigment in the retina and of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina are provided. These methods include the step of administering to a patient in need thereof a substituted C | 02-10-2011 |
| 20110152367 | PROCESS FOR THE PREPARATION OF FESOTERODINE WITH LOW IMPURITIES CONTENT - Disclosed is a process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having a low content of impurities such as tolterodine and tolterodine isobutyrate. | 06-23-2011 |
| 20110172304 | Sex Attractant of White Peach Scale and Attraction Method - Provided is an attractant of white peach scale capable of simplifying the synthesis of a sex pheromone of white peach scale and suppressing attraction of a parasitoid wasp which is a natural enemy of the white peach scale. More specifically, provided is a sex attractant of white peach scale comprising at least (R,Z)-(+)-3,9-dimethyl-6-isopropenyl-3,9-decadienyl priopionate and a geometric isomer (R,E)-(+)-3,9-dimethyl-6-isopropenyl-3,9-decadienyl priopionate at a weight ratio ranging from 80:20 to 40:60. In addition, provided is a method for attracting white peach scale by using said attractant. | 07-14-2011 |
| 20110207818 | DISINFECTING AND ANTIMICROBIAL COMPOSITIONS - Broad spectrum disinfecting and microbicidal compositions of biodegradable and environmentally friendly compositions containing esters formed from fatty organic alcohols and fatty carboxylic acids. These compositions display activities against the most resistant microbial forms including bacterial spores. The preparations can be used in health care, food processing, personal care and other industries where the use of harsh oxidizing chemicals is undesirable. | 08-25-2011 |
| 20110224297 | Methods of administering prostratin and structural analogs thereof - This invention relates generally to methods for administering prostratin or a structural analog or metabolite thereof to induce latent HIV-1 expression in mammalian cells. In certain embodiments, prostratin or a structural analog or metabolite thereof is administered by infusion. In an exemplary embodiment, the method of administering prostratin or a structural analog or metabolite thereof to induce latent HIV-1 expression further comprises the step of administering HAART. The invention also relates to kits comprising prostratin or a structural analog or metabolite thereof packaged with instructions for infusing the compound to induce latent HIV-1 expression. | 09-15-2011 |
| 20110237666 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF - A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia. | 09-29-2011 |
| 20110245337 | METHOD FOR ENHANCING THE DNA REPAIR PROCESS, TREATING DISORDERS ASSOCIATED WITH THE DNA REPAIR PROCESS, ENHANCING ANTITUMOR RESPONSE AND TREATING DISORDERS ASSOCIATED WITH ANTI-TUMOR RESPONSE IN MAMMALS BY ADMINISTERING PURIFIED QUINIC ACID AND/OR CARBOXY ALKYL ESTER - For use in mammals, methods for enhancing the anti-tumor response and treating disorders associated with anti-tumor response. The methods generally comprise non-topical administration of purified, isolated quinic acid alkyl acid or a carboxy alkyl ester with a non-toxic carrier or diluent. | 10-06-2011 |
| 20110245338 | CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF - The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C | 10-06-2011 |
| 20110257266 | Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated - Disclosed herein are therapeutic regimens for treating or ameliorating a visual disorder associate with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative or a pharmaceutically acceptable composition comprising a synthetic retinal derivative according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others. | 10-20-2011 |
| 20110281945 | GASTRIC ACID SECRETION INHIBITOR, AND POTASSIUM CHANNEL INHIBITOR - To provide a drug, quasi-drug, food or drink that can act as a gastric acid secretion suppressant or a potassium channel inhibitor by including a composition that can be safely used and can be inexpensively produced. Each of these products contains one or more cooling sensation compositions that are compounds providing cooling sensation in an amount sufficient for exhibiting the efficacy thereof in a living body to which the product is administered. | 11-17-2011 |
| 20110294882 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES - The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions. | 12-01-2011 |
| 20120046361 | ETHYL PYRUVATE COMPOSITIONS AND METHODS - Compositions and methods are disclosed for use of ethyl pyruvate to boost energy, endurance, or to feel good, or to lose weight. Pharmaceutical preparations having ethyl pyruvate are disclosed herein as well. | 02-23-2012 |
| 20120220655 | CRYSTALLINE FORMS OF FESOTERODINE FUMARATE AND FESOTERODINE BASE - Polymorphically pure crystalline forms of fesoterodine fumarate and fesoterodine base are described and characterized. | 08-30-2012 |
| 20120270942 | Spreading Active Agricultural Agents - Disclosed herein is a device for the application of agricultural active agents, wherein the device is suitable to be brought to the site of action in a manner temporally and spatially separated from the production process, and comprises a dispenser and non-water-soluble nanofibers and/or mesofibers charged with agricultural active agents. The polymers from which the nanofibers and/or mesofibers are made are preferably biodegradable. The agricultural active agents are selected from fungicides, herbicides, batericides, plant growth regulators and plant nutrients. These are preferably pheromones, kairomones and signaling substances. Furthermore, a method for the production of this device is disclosed, wherein the nanofibers and/or mesofibers charged with active agents are produced via electrospinning. The device is suitable to be used to bring agricultural active agents to the site of action in a manner temporally and spatially separated from the production of this device. The application is suitable to be carried out mechanically or automatically. This is preferably agricultural land used for fruit growing, viticulture, gardening or a commercial row crop. The device according to the present invention is particularly suitable to be used for the regulation of arthropods. | 10-25-2012 |
| 20120277315 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS - A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer. | 11-01-2012 |
| 20120295972 | Ester Derivatives of Bimatoprost Compositions and Methods - Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same. | 11-22-2012 |
| 20120316235 | MATING DISRUPTION METHOD USING ACETATE-CONTAINING MATING DISRUPTANT - Provided is a mating disruption method capable of bringing a stable and effective mating disruption result. Specifically provided is a mating disruption method comprising a step of starting to apply a mating disruptant after mating and oviposition of imagoes of the first generation of an insect pest are substantially over and before imagoes of the second generation of the insect pest emerge, the mating disruptant targeting at least one kind of insect pest which contains one or more kinds of acetates as a natural sex pheromone. | 12-13-2012 |
| 20130005806 | ANALYSIS OF TMLHE AND CARNITINE BIOSYNTHESIS FOR AUTISM DIAGNOSIS - Embodiments of the invention include determining whether an individual has autism spectrum disorder or is at risk for developing autism spectrum disorder or at risk for regression of or into autism spectrum disorder. Specific embodiments include the determination of indicative levels of carnitine or other metabolites in carnitine biosynthesis and may include assaying for mutations in TMLHE, including in exon 2, for example. In some cases one can assay for mutations in TMLHE in the absence of biochemical analysis of carnitine biosynthesis metabolites. An individual with deficiency in TMLHE and/or carnitine levels may be administered carnitine, acetylcarnitine, butyrobetaine, or a combination thereof, for example. | 01-03-2013 |
| 20130005807 | ANTIMICROBIAL COMPOSITION - The objective of the present invention is to provide an antimicrobial composition that can be safely used with a broad range of foods and beverages, cosmetics, drugs, and other similar products while showing growth inhibition activity against a wide variety of microorganisms. The present invention relates to the antimicrobial composition comprising at least one cooling agent selected from the group consisting of menthyl 3-hydroxybutanoate, 2-methyl-3-(menthoxy)propane-1,2-diol, 2-(menthoxy)ethanol, 3-menthoxypropan-1-ol, 2-(2-menthoxyethoxy)ethanol, and menthyl glyoxylate. | 01-03-2013 |
| 20130072556 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS - Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided. | 03-21-2013 |
| 20130072557 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION - A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C | 03-21-2013 |
| 20130072558 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION - A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C | 03-21-2013 |
| 20130079405 | Hydroxy Acid Ester Compound of Substituted Phenol, Preparation Method and Medical Use Thereof - Hydroxy acid compound of substituted phenyl ester, preparation method and medical use thereof are provided. The title compound is shown in formula (I), Y═C | 03-28-2013 |
| 20130096192 | NOVEL COMPOSITONS AND METHODS - Described herein are compositions (e.g., a pharmaceutical composition) and compounds of formula I, and their use in the treatment and/or prevention of diseases and disorders. | 04-18-2013 |
| 20130102663 | NUTRITIONAL COMPOSITION - An organoleptically acceptable composition containing a ketone body or a ketone body precursor including a hydroxybutyrate ester and a flavouring is provided and gives improved palatability and user adherence to the intended dose regime. The flavouring may be a bitter flavouring and the composition may further contain an adsorbent for the ketone such that on ingestion, the bitterness of the composition may be masked. The composition may be in the form of a solid, gel or liquid and provides increased blood ketone levels and may be used in therapy or in treating muscle impairment or fatigue. | 04-25-2013 |
| 20130123357 | Methods for Providing Enhanced Resveratrol Activity Using 4-Acetoxy-Resveratrol - The present invention relates to a method of providing enhanced resveratrol activity comprising: administering a therapeutically effective amount of 4-acetoxy-resveratrol for the treatment of and preventing physiological and pathophysiological conditions mediated by (1) sirtuins, (2) estrogen and anti-estrogen hormone actions and (3) chemical interventions important for male and female health, aging, anti-aging and age-related disorders. | 05-16-2013 |
| 20130131167 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS - This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss. | 05-23-2013 |
| 20130131168 | 1-MONOPROPIONINE COMPOUND AND ITS ISOMER 3-MONOPROPIONINE AS PRESERVING AGENTS FOR ANIMAL FEED, GRAINS AND ANIMAL-ORIGIN MEALS - An application method of 1-monopropionine compound and its isoform 3-monopropionine being used as preserving agents in animal feeds, corns, grains, and other food materials. The monopropionine compounds are obtained by esterification reaction of propionic acid and glycerol. The product is a translucent viscous liquid composition comprising monopropionine compounds and other components, such as free acid, or certain salt forms of propionate. The generated composition can be further distilled in glycerol. The final product can take a liquid form or a powder form. 1-monopropionine compound and its isoform 3-monopropionine function as preserving agent at a low effective dosage of about 0.05 to 1% (by weight), and preferably 0.1 to 0.3% (by weight). A preferable application condition of this method is to preserve animal feeds and corns under a low (about 2% to 12%) moisture condition. | 05-23-2013 |
| 20130172411 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present invention relates to stable pharmaceutical compositions comprising fesoterodine or salts thereof. In particular, the invention relates to pharmaceutical compositions of fesoterodine which does not contain sugar alcohols. The invention also relates to processes for making such compositions and use thereof in treating patients with urinary incontinence. | 07-04-2013 |
| 20130197082 | SHORT SYNTHESIS OF TOLTERODINE, INTERMEDIATES AND METABOLITES - A process is described for the preparation of intermediates which can be used for preparation of agents for urinary incontinence therapy, specifically to 2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol and its prodrugs. | 08-01-2013 |
| 20130296423 | PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation. | 11-07-2013 |
| 20130324606 | Ester Derivatives of Bimatoprost Compositions and Methods - Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same. | 12-05-2013 |
| 20130338224 | DECONTAMINATING COMPOSITION HAVING SIMULTANEOUSLY BACTERICIDAL, FUNGICIDAL AND VIROCIDAL PROPERTIES, METHODS FOR OBTAINING AND USING SAID COMPOSITION - The invention concerns a decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties, comprising as active components eugenol, eugenol acetate, vanillin and carvacrol, characterized in that said active constituents are present in the following percentages by weight: at least about 12% eugenol, at least about 3% eugenol acetate, at least about 0.1% vanillin and at least about 0.5% carvacrol. Said decontaminating composition can be used as liquid or solid soaps. It can also impregnate in liquid form fabrics and nonwoven fabrics such as garments for medical use, bed sheets, slip covers, surgery drape, dressings and gauze such as those applied to the skin of serious burn victims. | 12-19-2013 |
| 20140031425 | DISINFECTING AND ANTIMICROBIAL COMPOSITIONS - Broad spectrum disinfecting and microbicidal compositions of biodegradable and environmentally friendly compositions containing esters formed from fatty organic alcohols and fatty carboxylic acids. These compositions display activities against the most resistant microbial forms including bacterial spores. The preparations can be used in health care, food processing, personal care and other industries where the use of harsh oxidizing chemicals is undesirable. | 01-30-2014 |
| 20140045938 | Substituted Phenyl Aziridine Precursor Analogs for Inhibiting Androgen-Independent Prostate Cancer Cell Growth - Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as CpdA. The methods and compositions may be used for treating diseases, disorders, and conditions associated with glucocorticoid receptor activity, androgen receptor activity, or both, such as cancers, acne vulgaris, and alopecia. | 02-13-2014 |
| 20140107196 | ANTI-CANCER LEAD MOLECULE - Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘A’ (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative ‘A’ was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative ‘A’ could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative ‘A’ highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs. | 04-17-2014 |
| 20140163099 | ANTIMICROBIAL COMPOSITION - The objective of the present invention is to provide an antimicrobial composition that can be safely used with a broad range of foods and beverages, cosmetics, drugs, and other similar products while showing growth inhibition activity against a wide variety of microorganisms. The present invention relates to the antimicrobial composition comprising at least one cooling agent selected from the group consisting of menthyl 3-hydroxybutanoate, 2-methyl-3-(menthoxy)propane-1,2-diol, 2-(menthoxy)ethanol, 3-menthoxypropan-1-ol, 2-(2-menthoxyethoxy)ethanol, and menthyl glyoxylate. | 06-12-2014 |
| 20140194509 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF - A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia. | 07-10-2014 |
| 20140213647 | COMPOUND USEFUL FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME AND COMPOSITION INCLUDING SAME - The present invention provides a compound of formula (I) or a prodrug thereof useful for treating or preventing irritable bowel syndrome, and a composition comprising the compound as an active ingredient. Also, the present invention provides a method for treating or preventing irritable bowel syndrome, which comprises administrating a therapeutically or prophylactically effective amount of the compound or the composition to a subject in need of treating or preventing irritable bowel syndrome. | 07-31-2014 |
| 20140235713 | METHOD OF TREATING LYSOSOMAL STORAGE DISORDERS - Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof. | 08-21-2014 |
| 20140256808 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment - This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal. | 09-11-2014 |
| 20140296337 | CNS MODULATORS - A method is provided for treating a subject in need of therapy for depression, anxiety, impaired cognition and/or pain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide anti-depressant effect, cognition enhancing and/or analgesic effect. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM. | 10-02-2014 |
| 20150018415 | THERAPEUTIC COMPOSITIONS - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. | 01-15-2015 |
| 20150038582 | THERAPEUTIC REGIMENS AND METHODS FOR IMPROVING VISUAL FUNCTION IN VISUAL DISORDERS ASSOCIATED WITH AN ENDOGENOUS RETINOID DEFICIENCY - Therapeutic regimes for improving visual function in a subject having a deficiency in endogenously produced 11-cis retinal comprising administering the synthetic retinal derivative as a divided dose over 2-7 days then providing a resting period of 7-28 days after which the second dose of the synthetic retinal derivative is administered. Preferred synthetic retinal derivatives are 9- or 11-cis-retinyl esters. Disorders associated with deficiency in endogenously produced 11-cis retinal include retinitis pigmentosa and Leber congenital amaurosis. | 02-05-2015 |
| 20150057346 | METHODS OF MAINTAINING INTRAMUSCULAR MYOGLOBIN LEVELS, MAINTAINING MAXIMAL AEROBIC CAPACITY, AND ENHANCING THE OXIDATIVE CAPACITY OF MUSCLE IN A SUBJECT - Methods of maintaining intramuscular myoglobin levels, maintaining maximal aerobic capacity, and enhancing the oxidative capacity of muscle in a subject in need thereof are provided. Generally, the methods include administering an effective amount of β-hydroxy-β-methylbutyrate to the subject. The β-hydroxy-β-methylbutyrate may be administered as part of a nutritional composition. | 02-26-2015 |
| 20150065571 | KETONE BODY AND KETONE BODY ESTER FOR REDUCING MUSCLE BREAKDOWN - Use of a ketone body and a ketone body ester for preserving glycogen and/or protein, thereby reducing muscle breakdown and improving endurance during exercise and promoting muscle recovery following exercise. Also for retarding muscle wasting in aging and disease. (R)-3-hydroxybutyl (R)-3-hydroxybutyrate for use in reducing muscle glycogen and protein breakdown during exercise or decreasing muscle wasting in aging and disease. Certain esters of hydroxybutyrate monomers, particularly a monoester of | 03-05-2015 |
| 20150073048 | Antimicrobial Compositions and Related Methods of Use - Antimicrobial compositions comprising one or more compound components generally recognized as safe for human consumption, and related methods of use, such compositions and methods as can be employed in a wide range of agricultural, industrial, building, pharmaceutical and/or personal care products and applications. | 03-12-2015 |
| 20150133548 | COMBINATION OF BETA-HYDROXY-BETA-METHYLBUTYRATE, ARGININE AND GLUTAMINE FOR USE IN TREATING DIABETIC ULCERS - Disclosed is the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for use in a method of treating a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. 9. Also disclosed is the use of the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for the manufacture of a medicament for use in the treatment of a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. In certain embodiments, the combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine are orally administered via a nutritional composition. | 05-14-2015 |
| 20150133549 | Compositions and Methods for Treating Macular Degeneration - Methods of retarding formation of a lipofuscin pigment in the retina and of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina are provided. These methods include the step of administering to a patient in need thereof a substituted C | 05-14-2015 |
| 20150313817 | COMPOSITION OF MENTHOL AND MENTHYL LACTATE, ITS PREPARATION AND ITS USE AS A COOLING, FLAVOURING AND/OR FRAGRANCE AGENT - The present invention relates to a method of preparing liquid compositions essentially consisting of menthol and menthyl lactate and the use of such compositions as a cooling agent, flavouring agent and/or fragrance agent, products containing such compositions and methods of providing a physiological cooling effect by applying such compositions. | 11-05-2015 |
| 20150368187 | INHIBITORS OF THE TUMOR NECROSIS FACTOR RECEPTOR COMPLEX - The present invention relates to compounds of formula (I) that are inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions: Formula (I) | 12-24-2015 |
| 20160022553 | TEMPERATURE CHANGE COMPOSITIONS AND TISSUE PRODUCTS PROVIDING A COOLING SENSATION - Wiping products, such as facial tissues, contain a temperature change composition that can provide a cooling sensation when contacted with the skin of a user. The temperature change composition is structured emulsion that may include a phase change material, a carrier, a surfactant, and a crystalline initiator. The phase change materials, in one embodiment, can have a relatively high heat of fusion. When undergoing a phase change, the temperature change composition absorbs heat and thereby provides a cooling feeling or cooling sensation to the skin of a user. | 01-28-2016 |
| 20160029621 | Antimicrobial Compositions and Related Methods of Use - Antimicrobial compositions comprising one or more compound components generally recognized as safe for human consumption, and related methods of use, such compositions and methods as can be employed in a wide range of agricultural, industrial, building, pharmaceutical, personal care and/or animal care products and applications. | 02-04-2016 |
| 20160030314 | COMPOUND FOR USE IN PROTECTING SKIN - A method of protecting animal tissue particularly skin, from damage caused by radiation exposure, by contacting the tissue with a ketone ester, a method of protecting skin, reducing the deterioration of skin or maintaining or improving the properties of skin by applying topically to the skin a ketone body comprising (R)-3-hydroxybutyrate moieties is disclosed. A ketone body comprising (R)-3-hydroxybutyrate moieties, especially enantiomerically enriched R-1,3-hydroxybutyl-(R)-3-hydroxybutyrate, for such uses is also provided. | 02-04-2016 |
| 20160030347 | Stabilization Of Moisture-Sensitive Drugs - Described are stability-enhancing formulations of drugs that are sensitive to moisture. The formulations comprise co-granulates containing a moisture-sensitive drug and an excipient selected from fructose, xylitol, maltitol, and mixtures thereof. Also described are methods of producing a pharmaceutical tablet. The method comprises forming a blend of a moisture-sensitive drug and a first excipient selected from fructose, xylitol, maltitol, and mixtures thereof; spraying the blend with water to produce granules; drying and milling the granules; mixing a second excipient with the granules; and compressing into tablets. | 02-04-2016 |
| 20160031796 | ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES - Substantially stable to degradation Fesoterodine fumarate, a process for its preparation and a process for the synthesis of specific degradation impurities of Fesoterodine fumarate are disclosed. | 02-04-2016 |
| 20160044918 | METHOD OF CONTROLLING FILBERTWORM - There is provided a method of controlling filbertworm capable of reducing the number of release positions without changing a dosage amount per unit area. More specifically, there is provided a method of controlling filbertworm comprising the step of: providing E,E-8,10-dodecadienyl acetate or a composition comprising 80% by weight or more of E,E-8,10-dodecadienyl acetate at 1 to 100 release positions/ha to release the E,E-8,10-dodecadienyl acetate at a release rate of from 0.01 to 5 g/day/ha for mating disruption. | 02-18-2016 |
| 20160066572 | METHOD OF SANITIZING EDIBLE SEEDS, PARTICULARLY MUCILAGE PRODUCING SEEDS - Edible seeds are sanitized with a composition comprising water, a biocidal agent and a solvent. The composition is applied to the seeds and the seeds are later dried without first rinsing the seeds. The application rate may be 15% by weight of the seeds or less. The solvent may be a water-miscible alcohol such as ethanol or propylene glycol. When sanitizing mucilaginous seeds, the composition comprises one or more alcohols in an amount effective to inhibit the release of mucilage. The composition is initially applied as a mist to mucilaginous seeds. The biocidal agent may be an oxidizer such as peracetic acid. A treatment system includes an atomizing sprayer and a dryer, for example a fixed bed forced-air dryer. | 03-10-2016 |
| 20160193173 | KETONE BODIES AND KETONE BODY ESTERS AS BLOOD LIPID LOWERING AGENTS | 07-07-2016 |
| 20160198724 | Antimicrobial Compositions and Related Methods of Use | 07-14-2016 |
| 20160374979 | Method of Treatment of Alopecia with Monoterpenoids - The present application generally relates to topical formulations comprising monoterpenoid compounds which are effective inhibitors of FGF-5-dependent signalling in hair follicles or parts thereof, the manufacture of such topical formulations, and their use to reduce, delay or prevent loss of terminal hair caused by FGF-5 signalling in the hair follicle, such as in subjects suffering from, or having a propensity to develop, alopecia | 12-29-2016 |
